Author

Tove Selvin

Observed name: Selvin, Tove

Institution: Uppsala University

Observed institutions: Uppsala University, Uppsala University Hospital

ORCID: 0009-0000-3962-7933

Observed ORCID: 0009-0000-3962-7933

OpenAlex ID: A5090358732

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma

2022 · Frida Ek, Kristin Blom, et al. · Scientific Reports · 27

Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death

2023 · Tove Selvin, Malin Berglund, et al. · BMC Cancer · 21

Mebendazole is unique among tubulin-active drugs in activating the MEK–ERK pathway

2020 · Claes R. Andersson, Tove Selvin, et al. · Scientific Reports · 18

Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model

2022 · Tove Selvin, Erik Fasterius, et al. · Scientific Reports · 5

Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment

2024 · Tove Selvin, Malin Berglund, et al. · BMC Pharmacology and Toxicology · 2

Plasma Proteomic Profiling Identifies Prognostic Biomarkers in Mantle Cell Lymphoma

2024 · Tove Selvin, Patrick Nylund, et al. · Blood · 1

Plasma protein ADAMTS8 as a minimally invasive favorable prognostic biomarker in mantle cell lymphoma

2025 · Ingrid Glimelius, Tove Selvin, et al. · Blood

Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models

2024 · Tove Selvin, Malin Berglund, et al. · SLAS TECHNOLOGY

Rule-Based Machine Learning Analysis of the Blood Proteome Identifies MCL Patients with High Risk of Early Disease Progression

2024 · Patrick Nylund, Kossi D Abalo, et al. · Blood

Works count: 21

Citation count: 74

H-index: 4

I10-index: 3